Pasithea Therapeutics Announces The Completion Of Long-Term Chronic Toxicity Studies In Both Rats And Dogs With Its Lead Candidate PAS-004, Currently Being Investigated In A Phase 1 Clinical Trial In Advanced Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics has completed long-term chronic toxicity studies for its lead candidate PAS-004, a MEK inhibitor, in rats and dogs. The studies confirm a consistent safety profile, supporting ongoing Phase 1 trials in advanced cancer patients.
September 09, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics completed long-term toxicity studies for PAS-004, confirming its safety profile. This supports ongoing Phase 1 trials, potentially advancing PAS-004's development for cancer treatment.
The completion of long-term toxicity studies is a significant milestone for Pasithea's PAS-004, confirming its safety profile. This supports the ongoing Phase 1 trials, potentially advancing the drug's development and increasing investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100